Jane Street
CYTO

Jane Street’s Altamira Therapeutics Ltd CYTO Stock Holding History

Jane Street’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25
Closed -$18K – 11277
2021
Q4 		$18K Buy
+25
New +$16.8K ﹤0.01% 9824
2019
Q3 		– Sell
-27
Closed -$30K – 5943
2019
Q2 		$30K Buy
+27
New +$46.9K ﹤0.01% 5000

Other funds holding CYTO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Jane Street's CYTO Position: Q1 2022 in Review

Jane Street sold out of Altamira Therapeutics Ltd (CYTO) in Q1 2022, closing a stake of 25 shares — an estimated $18K sold.

Jane Street first reported a position in CYTO in Q2 2019 and held it in 2 quarters. The position peaked at $30K in Q2 2019. 14 funds tracked by Wall St. Rank hold CYTO as of Q1 2022.

  • Jane Street reported no remaining Altamira Therapeutics Ltd position as of Q1 2022 after selling out during the quarter.
  • Jane Street sold 25 Altamira Therapeutics Ltd shares in Q1 2022, an estimated $18K.
  • Jane Street first reported a position in Altamira Therapeutics Ltd in Q2 2019 and held it in 2 quarters.
  • Jane Street's Altamira Therapeutics Ltd position peaked at $30K in Q2 2019.
  • 14 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q1 2022.

Based on Jane Street's 13F filing for Q1 2022, filed 17 May 2022.